KalshiGeschlossenVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertDieser Markt ist geschlossen und wartet auf eine bestätigte Auflösung.
Wartet auf verifizierte Auflösung
CoinRithm wartet auf eine vom Anbieter bestätigte Auflösung, bevor dieser Markt als aufgelöst behandelt wird.
Aktuelle implizite Wahrscheinlichkeit
Before 2027 35%Führend unter 3 Optionen
Marktqualitat
35 / 100
Niedrige Qualität24h-Volumen
—
Liquidität
29.686 €
Hohe LiquiditätMarktdaten
Aktualisiert vor 8 Minuten
24. März 26, 14:00 UTC1. Sept. 26, 03:59 UTC
Trends
35%
20%
2%
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
FDA moves BPC-157 to Category 1 by which date?
PolymarketHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiWill we get AGI before 2027?
Manifold MarketsFDA approves skin cancer vaccine by which date?
PolymarketMeasles cases in 2026?
KalshiRegeln
If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.
Abwicklung über:Food and Drug Administration
- The Payout Criterion is satisfied by placement of BPC-157 in either Category 1 or Category 1 Bulk Drug Substances Under Evaluation on the 503A Bulk Drug Substances list, as either designation restores compounding eligibility.
- Removal from Category 2 alone, without placement in Category 1, does not satisfy the Payout Criterion.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Nov 1, 2026, then the market resolves to Yes.
- If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Jan 1, 2027, then the market resolves to Yes.
Offene Märkte
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No97%
- Yes3%
- Gesamtvolumen
- 15,6 Mio. €
- 24h-Volumen
- 18.019,1 €
POLYMARKETNew pandemic in 2026?
- No94.1%
- Yes5.9%
- Gesamtvolumen
- 920.141,3 €
- 24h-Volumen
- 4032,4 €
KALSHIMedtronic cardiovascular growth in Q2
- Above 8%92%
- Above 9%81%
- Above 11.5%53%
+6 weitere Ergebnisse
- Gesamtvolumen
- 2608,6 €
- 24h-Volumen
- 2608,6 €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 4000+1.0pt98%
- Above 6000+2.0pt61%
+2 weitere Ergebnisse
- Gesamtvolumen
- 868.057,2 €
POLYMARKETMeasles cases in U.S. in 2026?
- ↑3.5k100%
- ↑500+0.1pt100%
- ↑1k+0.1pt100%
+9 weitere Ergebnisse
- Gesamtvolumen
KALSHIPandemic in 2026?
- No95%
- Yes5%
- Gesamtvolumen
- 612.693,5 €
- 24h-Volumen
- 1245 €
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Which countries will report an Ebola disease case before October?
- What will RFK say during RNC Midterm Convention?
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will the FDA approve retatrutide?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
- Measles cases in U.S. by September 30?
- Will WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- How many West Nile neuroinvasive disease cases will be reported among New York City residents in 2026?
- Will 3 mg THC beverages qualify as hemp under federal law?
Häufige Fragen
- Wie stehen die aktuellen Quoten für When will the FDA reclassify BPC-157 to Category 1??
- Kalshi bewertet Before 2027 mit 35% (Stand: 10. September 2026).
- Wann wird When will the FDA reclassify BPC-157 to Category 1? entschieden?
- When will the FDA reclassify BPC-157 to Category 1? soll am 1. September 2026 entschieden werden.
- Wie wird When will the FDA reclassify BPC-157 to Category 1? abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If the FDA announces Reclassification of BPC-157 to Category 1 of the Bulk Drug Substances List before Sep 1, 2026, then the market resolves to Yes.